磷酸盐灌肠剂毒性——最新综述
本文系统检索2005—2021年PubMed、Google Scholar和Cochrane Reviews,评估磷酸盐灌肠剂毒性。共纳入25篇相关文献:9例儿童和16例成人的病例报告,以及样本量从24名健康志愿者到70,499例患者的较大病例系列或临床研究。病例报告发现7例成人死亡、无儿童死亡;儿童多表现为意识下降(6/9)和手足搐搦(4/9),成人报告低血压(4例)和QT延长(2例)。毒性常见原因为磷酸盐剂量过高或灌肠剂潴留,相关易感因素包括儿童先天性巨结肠、老年合并症和肾功能不全(2/5)。较大病例系列证实磷酸盐灌肠剂对血磷的急性影响与剂量和潴留时间相关,而非磷酸盐制剂未见此效应。
要点
- 病例报告共9例儿童和16例成人代谢异常;儿童最常见意识下降(6/9)和手足搐搦(4/9),无儿童死亡。
- 成人病例报告7例死亡;有临床特征描述的5例中低血压4例、QT延长2例。
- 毒性常见原因为磷酸盐剂量过高或灌肠剂潴留,导致磷酸盐吸收增加。
- 易感因素:儿童先天性巨结肠;老年合并症和肾功能不全(2/5)。
- 较大病例系列证实血磷急性升高与剂量和潴留时间相关,非磷酸盐制剂未见此效应。
适用人群与场景
- 使用磷酸盐灌肠剂的患者,尤其是幼儿(含先天性巨结肠患儿)和伴有合并症、肾功能不全的老年人。
处置流程与药物剂量
- 治疗以对症为主:电解质紊乱和低钙血症时给予静脉液体和钙盐,严重低血压时使用血管升压药。
- 3名儿童接受血液透析、1名儿童接受腹膜透析,均存活。
- 成人4例使用血液透析,其中2例死亡,血液透析未能阻止死亡。
- 作者认为,极端年龄患者应考虑其他低毒灌肠剂;若磷酸盐灌肠剂是唯一临床选择,应仔细监测生化后遗症。
红旗征与不能漏的情况
- 儿童意识下降(6/9)和手足搐搦(4/9)是常见表现。
- 成人低血压(4例)和QT延长(2例)。
- 磷酸盐剂量过高或灌肠剂潴留可导致磷酸盐吸收增加,是毒性常见原因。
研究设计与关键结果
- 系统检索2005—2021年文献,共489篇,25篇相关:7篇为9例儿童代谢异常的病例报告或小病例系列,6篇为16例成人的病例报告,9篇为较大病例系列或临床研究(样本量24名健康志愿者至70,499例患者)。
- 病例报告识别7例成人死亡、无儿童死亡;儿童最常见意识下降(6/9)和手足搐搦(4/9)。
- 成人有临床特征描述的5例中,低血压4例、QT延长2例。
- 儿童3例血液透析、1例腹膜透析,均存活;成人4例血液透析中2例死亡。
- 毒性常见因素为磷酸盐剂量过高或灌肠剂潴留;易感条件包括儿童先天性巨结肠、老年合并症和肾功能不全(2/5)。
- 血清磷酸盐或钙的绝对变化不是预后的准确指标。
- 较大病例系列和临床试验证实磷酸盐灌肠剂对血清磷酸盐有急性影响,与剂量和潴留时间相关;非磷酸盐制剂未见这些效应;这些病例系列中不良事件罕有报告。
证据类型、等级与局限
- 证据类型:系统文献综述,纳入病例报告、病例系列和临床研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,磷酸盐灌肠剂有潜在毒性,尤其对幼儿(含先天性巨结肠)和伴有合并症的老年人;仍需提高对磷酸盐灌肠剂风险的认识。
- 作者认为,其他低毒灌肠剂可用,极端年龄患者应考虑使用;若磷酸盐灌肠剂是唯一临床选择,应仔细监测生化后遗症。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Enemas containing phosphate are widely prescribed and may cause important adverse effects. A systemic review published in 2007 reported the literature on the adverse effects of phosphate enemas from January 1957 to March 2007 and identified 12 deaths. These were thought due to electrolyte disturbances, heart failure and kidney injury. These data raised concerns about the use of phosphate enemas in routine practice. Newer osmotic-based enema alternatives are now available that do not contain absorbable ions. We sought to review the literature since this review and evaluate the latest data on the toxicity of phosphate-containing enemas. To gain a fuller picture we included case series and larger studies as well as case reports.
OBJECTIVES: To review the toxicity of phosphate enemas, particularly with respect to acute metabolic consequences and their associated clinical features. To identify risk factors for metabolic toxicity and consider whether phosphate enemas should be relatively contra-indicated in specific patient groups.
METHODS: A systematic literature review was conducted in PubMed, Google Scholar, and Cochrane Reviews (2005-2021) using the search terms 'phosphate enema or sodium phosphate enema' or 'phosphate-based enema' or (phosphate AND enema) or (Fleet AND enema) or 'sodium phosphate laxatives' or 'sodium phosphate catharsis' or 'sodium phosphate cathartic'. Relevant papers were read, and data were extracted.
RESULTS: The searches identified 489 papers of which 25 were relevant: seven papers were case reports or small case series of metabolic abnormalities from the use of phosphate enemas in nine children, six were case reports on 16 adults. Nine papers were large case series or clinical studies that included data on systemic metabolic effects, of varying size from 24 healthy volunteers to a cohort of 70,499 patients. Case reports identified seven adult deaths but none in children. Children most often presented with decreased consciousness (6/9), and tetany (4/9). In adults overall only five cases had clinical features reported, hypotension was seen in four and QT prolongation in two. Treatment was generally symptomatic, with intravenous fluid and calcium salts for electrolyte changes and hypocalcaemia, and vasopressors for severe hypotension. Haemodialysis was used in three children and peritoneal dialysis in one, all of whom survived. In adults, haemodialysis did not prevent death in two of four cases in whom it was used. Common factors underlying toxicity were inappropriately high phosphate dose, or enema retention, both resulting in greater absorption of phosphate. Associated pre-disposing conditions included Hirschsprung disease in children and co-morbidity and renal impairment (2/5) in older adults. Absolute reported changes in serum phosphate or calcium were not accurate indicators of outcome. Larger case series and clinical trials confirm an acute effect of phosphate enemas on serum phosphate, which was related to both dose and retention time. These effects were not seen with non-phosphate preparations. In these cases series, adverse events were rarely reported.
CONCLUSION: Phosphate enemas are potentially toxic, particularly in young children with Hirschsprung disease and in the elderly with co-morbidity. Raised awareness of the risk of phosphate enemas is still required. Other less toxic enema preparations are available and should be considered in patients at extremes of age. If phosphate enemas are the only clinical option careful monitoring of biochemical sequelae should be undertaken.
参考来源
- Hamilton Smith R, Eddleston M, Bateman DN, et al. Toxicity of phosphate enemas - an updated review. Clin Toxicol (Phila). 2022. PMID: 35510830. doi:10.1080/15563650.2022.2054424
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。